Glaucoma and Retinopathy Screening Study
This study is looking at a new way to screen for glaucoma, an eye disease that can cause vision loss. It combines an artificial intelligence (AI) program that analyzes pictures of the back of your eye (fundus photographs) with eye pressure measurements and, if needed, a side vision test using a virtual reality headset. The goal is to see if this approach can find glaucoma earlier, especially in people with diabetes who are at higher risk. You can join if you are 40 or older, have diabetes, and are already getting AI-based screening for diabetic retinopathy. The study will measure how well this new screening method detects glaucoma over one year.
- Study design
- This is an interventional study planning to enroll 2000 participants. It is designed to evaluate a new AI-based screening program.
- What's involved
- You will have an image of the back of your eye taken, your eye pressure measured, and potentially a side vision test using a headset.
- Compensation
- Not stated in the trial record.
- Follow-up
- Glaucoma detection will be measured at 1 year from initial screening.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
The Glaucoma and Retinopathy Screening Study
At a glance
Conditions
Where it's being run
7 sites across 1 statesStudy leadership
- David S Friedman, MD, PhD, MPH · PRINCIPAL_INVESTIGATOR · Massachusetts Eye and Ear
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Glaucoma detection1 year from initial screening
This primary outcome measure will assesses the proportion of participants who receive a glaucoma diagnosis in the combined DED and glaucoma screening group compared to the DED-only screening group. Glaucoma diagnosis in the intervention group is based on AI-assisted analysis of fundus photography, intraocular pressure, and virtual reality perimetry testing for confirmation.